VacciTalks: Vaccine Development from Bench to Patient: Myths and Reality 

Welcome to VacciTalks by Alira Health – exclusive educational appointments with the leading vaccine experts

Published on:
January 21, 2022

Is vaccine recommendation after registration really needed? Is regulatory approval the same as a recommendation? Can a research laboratory bring its own vaccine to a market?

On the 24th of February for the first VacciTalk episode “Vaccine Development from Bench to Patient: Myths and Reality ” we sat down with Prof. Dr. Joe Schmitt, vaccine expert with 40 years of experience, and discovered answers to these and many other questions and debunked some of the most common myths related to vaccine development in a live discussion.

Watch the replay of VacciTalk “Vaccine Development from Bench to Patient: Myths and Reality ” and learn about:
  • The common misconceptions related to the vaccine development
  • Challenges these misconceptions can cause
  • Ways to overcome them
Joe Schmitt

Joe is board certified in paediatrics, infectious diseases, microbiology, and epidemiology and held a chair as professor of vaccine development at the Gutenberg University, Mainz, Germany.

Joe’s clinical studies were cornerstones for global licenses of acellular pertussis and respective combination vaccines.  Joe was a member (1995-2007) and chair of the German vaccination advisory board (STIKO) for 3 consecutive terms (1997-2007) and advisor to the Paul Ehrlich Institute (PEI) and different WHO committees, including SAGE and the GACVS-groups. He was the Global Head, Medical Affairs with Novartis Vaccines during the time of the influenza pandemic (about 2010) and he joined Pfizer in 2011 and was Vice President for Medical-, Developmental-, Scientific- and Clinical-Affairs (MDSCA) and Global Lead Viral Vaccines until May 2021.  

Currently, Joe is Editor-in-Chief with Global Health Press (GHP) in Singapore and he is also Strategic and Scientific Advisor with “Vaccelerate” at the Cologne University, Germany. 

Our hosts 

Bernd Schollmeier, Vice President, Global Market Access Vaccines 
Bernd Schollmeier

A vaccine expert with more than 30 years of experience, Bernd has been responsible for a range of global pricing and market access initiatives for vaccines in the international pharmaceutical companies — from delivering a range of solutions across development and strategic market access considerations for trial design to value demonstration in P&R negotiations as well as commercialization strategies.  

Kenny Carberry, Associate Director, Clinical Development 
Kenny Carberry

Kenny’s background covers a wide array of indications across pharma, medical devices, and digital health. He has multiple years of experience in clinical trial operations and management and offers a unique perspective on the clinical development lifecycle from generating a comprehensive strategy through executing a successful trial. 

About VacciTalks

VacciTalks is a series of unique appointments with the Key Opinion Leaders of the vaccine world. During each of the episodes, our hosts Bernd Schollmeier and Kenny Carberry will sit down with their guests and talk about the topics that disrupt the vaccine world right now – from development challenges to COVID-19 impact, new technologies, and much more.  

Follow us on LinkedIn and never miss the next VacciTalk!  

Related news

Events January 27, 2023
Alira Health and Biocat Startup Support Program Presentation
Biocat and Alira Health partnered to foster Market Access for startups. Alira Health, a global healthcare advisory and technology company, and Biocat, a strategic stakeholder building(...)
Market Access Startups
Publications January 20, 2023
Insights on Market Access
To get her perspective on market access and what to expect in 2023, we spoke with Nerea Blanqué, Senior Vice President of Market Access and Pricing at Alira Health.
Market Access Medical Devices Pharma
Publications December 21, 2022
2022 Recap: Your Favorite Alira Health Publications
In 2022, the Alira Health team of scientists, strategists, economists, clinicians, and biostatisticians shared actionable insights, industry thought leadership, and leading-edge guidance(...)
Clinical Digital Health Market Access MedTech Pharma Regulatory
News November 15, 2022
Alira Health Partners with Policy Matters to Foster Market Access in the UK
Alira Health, a global advisory and clinical research firm whose mission is to humanize healthcare and life sciences, announces its partnership with leading UK market access specialist(...)
Digital Health Healthcare Consulting Market Access
News November 10, 2022
Alira Health and GDMH together to boost Life Sciences innovation
The companies join forces for collaborative research and co-development of projects in the fields of Digital Health, Real-World Evidence and Market Access.
Clinical Trials Digital Health DTx Market Access Real-World Evidence RWE
Events October 7, 2022
Debate Sobre los IPT en Oncología
We are pleased to announce our next event, “Debate Sobre los IPT en Oncología,” focusing on price and reimbursement (P&R) of vital oncology and oncohematology therapies.
Market Access Product Development Regulatory
Publications October 5, 2022
Relative Weight of the Variables Evaluated Through the Therapeutic Positioning Reports in the Pricing and Reimbursement of Oncological and Oncohematology Medicines in Spain
Discover how companies’ target prices are impacted by the different variables leveraged during the P&R process for oncology and oncohematology’s first indication.
Market Access Oncology Spain
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.